Current NSIV member, Genomic Expression announced on January 3, 2018 the receipt of a $4.2M Grant to validate its OneRNA™ liquid biopsy platform in Bladder Cancer. The Horizon 2020 grant is one of the largest allocations of support from the EU ever given to a small biotech company. Overall, this solution will guide patients toward more effective treatments, reduce the number of cystoscopies and biopsies, identify patients with a higher likelihood of responding to new, expensive immunotherapy treatments, and, finally, reduce the cost of bladder-cancer treatment. Read the entire press release here.
Leave a Comment